Postpartum Blood Clot Risk: Patient &
A new study finds patients are willing to use injections to prevent postpartum blood clots after C-sections, but both patients and clinicians see room for
Patients and clinicians see a need for better communication and more research on postpartum blood clot risk and prevention. A new qualitative study interviewed 15 postpartum patients and 10 obstetric clinicians at a single academic medical center to explore their perspectives on venous thromboembolism (VTE) risk after cesarean delivery and the use of preventive blood-thinning injections.
Patient Perspectives on Risk and Prevention
All patients in the study were educated about their elevated risk for a blood clot after a cesarean delivery. They were also told the rationale for pharmacologic thromboprophylaxis, which typically involves self-injections. Patients reported experiencing discomfort from the injections, including bruising and pain at the injection site.
Despite this discomfort, patients reflected a willingness to use the therapy. Their primary motivation was to reduce their personal risk of a life-threatening VTE event and to protect themselves. The study found patients identified some gaps in their knowledge about the condition and its prevention. They also expressed a desire for enhanced educational materials and a willingness to participate in future research on the topic.
Clinician Views and Barriers
Clinicians in the study endorsed providing counseling on VTE risk and thromboprophylaxis to their postpartum patients. However, they identified several barriers to optimal management. Clinicians also recognized uncertainties surrounding the best approaches for prevention.
These healthcare providers valued research that could lead to improved, evidence-based guidelines. They emphasized the necessity of studies that would inform more precise, individualized VTE risk estimates for patients. Research into the exact efficacy and risks of preventive medications was also highlighted as a priority.
Opportunities for Improvement
The study concludes that while routine education on this risk is being provided, there are clear opportunities to improve how the information is communicated. Both groups, patients who have undergone cesarean delivery and the clinicians who care for them, identified the necessity of further research.
This research is needed to create precise, individualized VTE risk estimates. It is also required to better understand the efficacy and risks of thromboprophylaxis medications used in the postpartum period. The study was led by Ann M. Bruno, who received funding support from the Women's Reproductive Health Research K12 program.
